Ad
related to: cenlax 7.5mg tablets adult diabetes drug- Patient Profiles
Meet Stelo Patients.
Learn who benefits from Stelo.
- Order Stelo
For your practice and bring the
benefit of Stelo to your patients.
- Explore Stelo
Over 25 years of innovation.
Technology from a company you trust
- Provider Site
Empower Your Patients.
No Prescription Needed.
- Patient Profiles
Search results
Results from the WOW.Com Content Network
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
In plant form, it has been used at least since the 700s AD. [7] It is on the World Health Organization's List of Essential Medicines. [8] It is available as a generic medication. [1] [6] In 2022, it was the 280th most commonly prescribed medication in the United States, with more than 600,000 prescriptions.
A Novo Nordisk-sponsored 2021 study followed nearly 2,000 adults with a body mass index (BMI) of 30 or more and without diabetes. It looked at 2.4 milligrams of weekly semaglutide versus a placebo ...
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. [1] [2] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
Some drugs used to treat type 2 diabetes could also help lower a person’s risk of neurodegenerative diseases, such as Alzheimer’s. Image credit: martin-dm/Getty Images.
A recent study has shown that people who take SGLT-2 inhibitors for type 2 diabetes management have a 35% lower diabetes risk, overall. A diabetes drug may help prevent dementia, new research ...
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
(Reuters) - AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA's ...
Ad
related to: cenlax 7.5mg tablets adult diabetes drug